- Home
- OCX vs LPCN Comparison
OCX vs LPCN Comparison
Compare OCX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCX
- LPCN
- Stock Information
- Founded
- OCX 2009
- LPCN 1997
- Country
- OCX United States
- LPCN United States
- Employees
- OCX N/A
- LPCN N/A
- Industry
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- OCX Health Care
- LPCN Health Care
- Exchange
- OCX Nasdaq
- LPCN Nasdaq
- Market Cap
- OCX 38.7M
- LPCN 36.8M
- IPO Year
- OCX N/A
- LPCN N/A
- Fundamental
- Price
- OCX $2.61
- LPCN $4.94
- Analyst Decision
- OCX Buy
- LPCN Strong Buy
- Analyst Count
- OCX 3
- LPCN 1
- Target Price
- OCX $4.42
- LPCN $10.00
- AVG Volume (30 Days)
- OCX 64.0K
- LPCN 30.8K
- Earning Date
- OCX 11-12-2024
- LPCN 11-07-2024
- Dividend Yield
- OCX N/A
- LPCN N/A
- EPS Growth
- OCX N/A
- LPCN N/A
- EPS
- OCX N/A
- LPCN N/A
- Revenue
- OCX $709,000.00
- LPCN $7,922,926.00
- Revenue This Year
- OCX N/A
- LPCN N/A
- Revenue Next Year
- OCX $167.93
- LPCN N/A
- P/E Ratio
- OCX N/A
- LPCN N/A
- Revenue Growth
- OCX N/A
- LPCN N/A
- 52 Week Low
- OCX $2.29
- LPCN $2.38
- 52 Week High
- OCX $4.34
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- OCX 30.23
- LPCN 44.02
- Support Level
- OCX $2.73
- LPCN $4.79
- Resistance Level
- OCX $3.04
- LPCN $5.40
- Average True Range (ATR)
- OCX 0.14
- LPCN 0.54
- MACD
- OCX -0.03
- LPCN -0.12
- Stochastic Oscillator
- OCX 0.00
- LPCN 16.01
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.